Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499763 | 0.88 | TSHR (0.46) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL31222882 | 0.86 | TSHR (0.44) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL15238178 | 0.86 | TSHR (0.44) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL21383670 | 0.86 | TSHR (0.44) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL12737575 | 0.80 | TSHR (0.74) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL11289831 | 0.78 | TSHR (0.70) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL18071751 | 0.78 | TSHR (0.47) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL576408 | 0.78 | TSHR (0.88) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL7254965 | 0.78 | TSHR (0.58) | TSHRALDH1A1 | |
| SCHEMBL14052611 | 0.77 | KDM4E (0.50) | TSHRKDM4EUSP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| EP-2459560-B1 | RING-ANNULATED DIHYDROPYRROLO[2,L-A]ISOQUINOLINES | MERCK SHARP & DOHME (NL) | 2015-08-19 | — | — | EP | disclosed |
| US-8431564-B2 | Ring-annulated dihydropyrrolo[2,1-α]isoquinolines | MERCK SHARP & DOHME B.V. (NL) | 2013-04-30 | — | — | US | disclosed |
| EP-2459560-A1 | RING-ANNULATED DIHYDROPYRROLO[2,L-A]ISOQUINOLINES | MSD Oss B.V. (NL) | 2012-06-06 | — | — | EP | disclosed |
| US-20110028450-A1 | Ring-annulated dihydropyrrolo[2,1-alpha]isoquinolines | N.V. ORGANON (NL) | 2011-02-03 | — | — | US | disclosed |
| US-20110028450-A1 | Ring-annulated dihydropyrrolo[2,1-alpha]isoquinolines | N.V. ORGANON (NL) | 2011-02-03 | — | — | US | disclosed |
| WO-2011012600-A1 | RING-ANNULATED DIHYDROPYRROLO[2,L-A]ISOQUINOLINES | N.V. ORGANON (NL) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, CRKL, OSTC | TSHR 553/4885KDM4E 1946/4885USP2 1988/4885 |
| US-20110028450-A1 | Ring-annulated dihydropyrrolo[2,1-alpha]isoquinolines | CATSPER1, QDPR, NASP | TSHR 2975/4885KDM4E 2195/4885USP2 4420/4885 |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | TSHR 3167/4885KDM4E 542/4885USP2 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.